Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics

Abstract JS-K, a nitric oxide-releasing diazeniumdiolates, is effective against various tumors. We have discovered that JS-K was effective against Hepatitis B virus (HBV)-positive HepG2.2.15 cells. This study used iTRAQ to identify differentially expressed proteins following JS-K treatment of HepG2....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhengyun Liu, Yan Xu, Wanling Zhang, Xinghong Gao, Guo Luo, Hong Song, Jie Liu, Huan Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/73c4d0bda3a94493a3e041b00acac831
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73c4d0bda3a94493a3e041b00acac831
record_format	dspace
spelling	oai:doaj.org-article:73c4d0bda3a94493a3e041b00acac8312021-12-02T15:45:32ZIdentification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics10.1038/s41598-021-90001-32045-2322https://doaj.org/article/73c4d0bda3a94493a3e041b00acac8312021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90001-3https://doaj.org/toc/2045-2322Abstract JS-K, a nitric oxide-releasing diazeniumdiolates, is effective against various tumors. We have discovered that JS-K was effective against Hepatitis B virus (HBV)-positive HepG2.2.15 cells. This study used iTRAQ to identify differentially expressed proteins following JS-K treatment of HepG2.2.15 cells. Silenced Transgelin (shTAGLN-2.15) cells were constructed, and the cell viability was analyzed by the CCK8 assay after treatment with JS-K. There were 182 differentially expressed proteins in JS-K treated-HepG2.2.15 cells; 73 proteins were up-regulated and 109 proteins were down-regulated. These proteins were categorized according to GO classification. KEGG enrichment analysis showed that Endocytosis, Phagosome and Proteoglycans were the most significant pathways. RT-PCR confirmed that the expression levels of TAGLN, IGFBP1, SMTN, SERPINE1, ANXA3, TMSB10, LGALS1 and KRT19 were significantly up-regulated, and the expression levels of C5, RBP4, CHKA, SIRT5 and TRIM14 were significantly down-regulated in JS-K treated-HepG2.2.15 cells. Western blotting confirmed the increased levels of USP13 and TAGLN proteins in JS-K treated-HepG2.2.15 cells. Molecular docking revealed the binding of JS-K to TAGLN and shTAGLN-2.15 cells were resistant to JS-K cytotoxicity, suggesting that TAGLN could be an important target in JS-K anti-HBV-positive liver cancer cells. These proteomic findings could shed new insights into mechanisms underlying the effect of JS-K against HBV-related HCC.Zhengyun LiuYan XuWanling ZhangXinghong GaoGuo LuoHong SongJie LiuHuan WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zhengyun Liu Yan Xu Wanling Zhang Xinghong Gao Guo Luo Hong Song Jie Liu Huan Wang Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics
description	Abstract JS-K, a nitric oxide-releasing diazeniumdiolates, is effective against various tumors. We have discovered that JS-K was effective against Hepatitis B virus (HBV)-positive HepG2.2.15 cells. This study used iTRAQ to identify differentially expressed proteins following JS-K treatment of HepG2.2.15 cells. Silenced Transgelin (shTAGLN-2.15) cells were constructed, and the cell viability was analyzed by the CCK8 assay after treatment with JS-K. There were 182 differentially expressed proteins in JS-K treated-HepG2.2.15 cells; 73 proteins were up-regulated and 109 proteins were down-regulated. These proteins were categorized according to GO classification. KEGG enrichment analysis showed that Endocytosis, Phagosome and Proteoglycans were the most significant pathways. RT-PCR confirmed that the expression levels of TAGLN, IGFBP1, SMTN, SERPINE1, ANXA3, TMSB10, LGALS1 and KRT19 were significantly up-regulated, and the expression levels of C5, RBP4, CHKA, SIRT5 and TRIM14 were significantly down-regulated in JS-K treated-HepG2.2.15 cells. Western blotting confirmed the increased levels of USP13 and TAGLN proteins in JS-K treated-HepG2.2.15 cells. Molecular docking revealed the binding of JS-K to TAGLN and shTAGLN-2.15 cells were resistant to JS-K cytotoxicity, suggesting that TAGLN could be an important target in JS-K anti-HBV-positive liver cancer cells. These proteomic findings could shed new insights into mechanisms underlying the effect of JS-K against HBV-related HCC.
format	article
author	Zhengyun Liu Yan Xu Wanling Zhang Xinghong Gao Guo Luo Hong Song Jie Liu Huan Wang
author_facet	Zhengyun Liu Yan Xu Wanling Zhang Xinghong Gao Guo Luo Hong Song Jie Liu Huan Wang
author_sort	Zhengyun Liu
title	Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics
title_short	Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics
title_full	Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics
title_fullStr	Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics
title_full_unstemmed	Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics
title_sort	identification of targets of js-k against hbv-positive human hepatocellular carcinoma hepg2.2.15 cells with itraq proteomics
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/73c4d0bda3a94493a3e041b00acac831
work_keys_str_mv	AT zhengyunliu identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT yanxu identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT wanlingzhang identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT xinghonggao identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT guoluo identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT hongsong identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT jieliu identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics AT huanwang identificationoftargetsofjskagainsthbvpositivehumanhepatocellularcarcinomahepg2215cellswithitraqproteomics
_version_	1718385757904699392

Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics

Ejemplares similares